Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–116.

Article  PubMed  Google Scholar 

Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676–98.

Article  PubMed  Google Scholar 

Cox JT, Eliott D, Sobrin L. Inflammatory Complications of Intravitreal Anti-VEGF Injections. J Clin Med. 2021;10:981.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng S-Y, Luo Y, Malachi A, Ko J, Su Q, Xie J, et al. Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis. Hum Gene Ther. 2021;32:649–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai C, Waduge P, Ji L, Huang C, He Y, Tian H, et al. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cell Mol Life Sci. 2022;79:63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldhardt R, Batawi HIM, Rosenblatt M, Lollett IV, Park JJ, Galor A. Effect of Anti-Vascular Endothelial Growth Factor Therapy on Corneal Nerves. Cornea 2019;38:559–64.

Article  PubMed  Google Scholar 

Zhu Z-Y, Meng Y-A, Yan B, Luo J. Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy. Int J Ophthalmol. 2021;14:1647–52.

Article  PubMed  PubMed Central  Google Scholar 

Elnahry AG, Abdel-Kader AA, Habib AE, Elnahry G, Raafat KA, Elrakhawy K. Review on Recent Trials Evaluating the Effect of Intravitreal Injections of Anti-VEGF Agents on the Macular Perfusion of Diabetic Patients with Diabetic Macular Edema. Rev Recent Clin Trials. 2020;15:188–98.

CAS  PubMed  PubMed Central  Google Scholar 

Abri Aghdam K, Reznicek L, Soltan Sanjari M, Klingenstein A, Kernt M, Seidensticker F. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol. 2017;11:331–6.

Article  PubMed  PubMed Central  Google Scholar 

Resch MD, Balogh A, Deák GG, Nagy ZZ, Papp A. Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens. PLoS One. 2020;15:e0229388.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray SK, Manz SN. Brain health assessment in macular degeneration patients undergoing intravitreal anti-vascular endothelial growth factor injections (the bham study): An Interim Analysis. Retina. 2021;41:1748–53.

Article  CAS  PubMed  Google Scholar 

Sultana J, Scondotto G, Cutroneo PM, Morgante F, Trifirò G. Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. Front Pharm. 2020;11:315.

Article  Google Scholar 

Dedania VS, Bakri SJ. Current perspectives on ranibizumab. Clin Ophthalmol. 2015;9:533–42.

PubMed  PubMed Central  Google Scholar 

Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36:303–11.

Article  PubMed  PubMed Central  Google Scholar 

Castro BFM, Steel JC, Layton CJ. AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies. BioDrugs. 2024;38:73–93.

Article  PubMed  Google Scholar 

Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunn EN, Hariprasad SM, Sheth VS. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retin. 2017;48:100–4.

Article  Google Scholar 

Reid CA, Nettesheim ER, Connor TB, Lipinski DM. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. Sci Rep. 2018;8:11763.

Article  PubMed  PubMed Central  Google Scholar 

LeBlanc ME, Wang W, Chen X, Caberoy NB, Guo F, Shen C, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med. 2017;214:1029–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rong X, Tian H, Yang L, Li W. Function-first ligandomics for ocular vascular research and drug target discovery. Exp Eye Res. 2019;182:57–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji L, Waduge P, Wu Y, Huang C, Kaur A, Oliveira P, et al. Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy. Int J Mol Sci. 2023;24:10531.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji L, Waduge P, Hao L, Kaur A, Wan W, Wu Y, et al. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization. FASEB J. 2022;36:e22106.

Article  CAS  PubMed  Google Scholar 

Huang C, Ji L, Kaur A, Tian H, Waduge P, Webster KA, et al. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice. Biomedicines. 2023;11:1910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. Drug information for Eylea. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf.

Droho S, Rajesh A, Cuda CM, Perlman H, Lavine JA. CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization. JCI Insight. 2023;8:e168142.

Article  PubMed  PubMed Central  Google Scholar 

Grishanin R, Vuillemenot B, Sharma P, Keravala A, Greengard J, Gelfman C, et al. Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration. Mol Ther. 2019;27:118–29.

Article  CAS  PubMed  Google Scholar 

Gelfman CM, Grishanin R, Bender KO, Nguyen A, Greengard J, Sharma P, et al. Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema. J Ocul Pharm Ther. 2021;37:181–90.

Article  CAS  Google Scholar 

Lai C-M, Shen W-Y, Brankov M, Lai YKY, Barnett NL, Lee SY, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005;12:659–68.

Article  CAS  PubMed  Google Scholar 

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 2011;19:260–5.

Article  CAS  PubMed  Google Scholar 

Hughes CP, O’Flynn NMJ, Gatherer M, McClements M, Scott JA, MacLaren R, et al. AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. Mol Ther Methods Clin Dev. 2019;13:86–98.

Article  CAS  PubMed  Google Scholar 

Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. Mol Asp Med. 2012;33:487–509.

Article  CAS  Google Scholar